Cancer Genetics (CGIX) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cancer Genetics, Inc. Announces 39% Revenue Increase and Provides Recent Company Highlights
May 10, 2016 4:02 PM EDTCompany reports record quarterly revenues of $6.1 million, an increase of 39% over Q1 2015 and 11% over Q4 2015Significant expansion of new Immuno-Oncology (IO) test offering, with expansion into 12 active IO focused clinical trials with leading global companiesSigned contracts for expected future revenues with biotech and pharma companies increases to over $41 millionCancer Genetics to host conference call today, Tuesday, May 10, 2016, at 5:00 pm Eastern Time / 2:00 pm Pacific Time
RUTHERFORD, N.J., May 10, 2016 (GLOBE NEWSWIRE) --... More
